ipragliflozin + sulfonylurea

**ipragliflozin + sulfonylurea** is a combination therapy comprising two classes of oral antidiabetic agents used to treat type 2 diabetes mellitus. Ipragliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that lowers blood glucose by preventing renal glucose reabsorption, thereby increasing urinary glucose excretion. Sulfonylureas are a class of small molecule drugs that act as insulin secretagogues by stimulating pancreatic beta cells to release insulin. The combination targets two distinct pathogenic mechanisms of type 2 diabetes, providing additive glucose-lowering effects. Ipragliflozin generally has a low risk for hypoglycemia, but risk increases markedly when combined with insulin or sulfonylureas. Clinical studies indicate the combination can improve glycemic control, but may require adjusting the dose of sulfonylurea to mitigate hypoglycemia risk[1][3][5].